Involvement of purinergic nerves in the NANC inhibitory junction potentials in pigeon oesophageal smooth muscle.
1. Electrical field stimulation (EFS) (0.5 ms in train of 2-32 Hz for 300 ms) in smooth muscle of pigeon oesophagus, in the presence of atropine (1 microm) and guanethidine (1 microm), elicited an inhibitory response consisting of a transient hyperpolarization (inhibitory junction potential, IJP) associated with muscle relaxation. 2. Sodium nitroprusside (SNP, 100 microm) induced hyperpolarization correlated to mechanical relaxation. 3. The nitric oxide (NO) synthase inhibitor N(omega)-nitro-l-arginine (from 0.1 to 100 microm) caused a concentration-dependent reduction of electromechanical response to EFS indicating a role for NO in this response. 4. Apamin (1 microm) reduced both IJP and relaxation to EFS but was without effect on the response to SNP indicating a role for purines, which are also blocked by apamin. 5. Adenosine, AMP, ADP and ATP (all from 1 microm to 1 mm) application caused transient hyperpolarization and muscular relaxation with the following order of potency: adenosine > AMP > ADP > ATP. 6. Inhibitory responses evoked by purines are TTX (1 microm) insensitive but they were inhibited by apamin. This indicates that a purine component for the non-adrenergic non-cholinergic (NANC) response exists but the purine receptor site is not located on the neurone. 7. Overall these results suggest that NANC inhibitory response elicited by EFS presents two different components apamin-sensitive, probably purines-mediated and apamin-insensitive probably NO-mediated as apamin only partially block the response to EFS.
Vetri
T
T
Dipartimento di Biologia cellulare e dello sviluppo, Laboratorio di Fisiologia, Università degli Studi di Palermo, Viale delle Scienze Parco d'Orleans II 90128 Palermo, Italy.
Postorino
A
A
Fileccia
R
R
Bonvissuto
F
F
Abbadessa Urso
S
S
D000227:Adenine Nucleotides / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000241:Adenosine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D018663:Adrenergic Agents / Q000494:pharmacology; D000818:Animals; D001030:Apamin / Q000494:pharmacology; D001285:Atropine / Q000494:pharmacology; D001341:Autonomic Nervous System / Q000187:drug effects / Q000502:physiology*; D010856:Columbidae / Q000502:physiology*; D004558:Electric Stimulation; D004594:Electrophysiology; D004947:Esophagus / Q000187:drug effects / Q000294:innervation* / Q000502:physiology; D006145:Guanethidine / Q000494:pharmacology; D066298:In Vitro Techniques; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology; D009130:Muscle, Smooth / Q000187:drug effects / Q000294:innervation* / Q000502:physiology; D009469:Neuromuscular Junction / Q000187:drug effects / Q000502:physiology*; D018408:Patch-Clamp Techniques; D011687:Purines / Q000494:pharmacology*
D000227:Adenine Nucleotides; D018663:Adrenergic Agents; D018727:Muscarinic Antagonists; D011687:Purines; D001030:Apamin; D001285:Atropine; D000241:Adenosine; D006145:Guanethidine